Biofilms are colonies of bacteria on a surface that are insensitive to systemic antibiotics and topical antimicrobials. Chronic wounds, burns, surgical wounds, and all surgical implants are prone to development of mature biofilms that can delay healing by several months and lead to septic shock or amputations.
“This new grant will support late-stage development of an advanced version of our FDA-cleared Microlyte® Matrix product, which will contain a unique combination of silver and gallium metal ions,” said Ankit Agarwal, co-founder and CEO of the company and Principal Investigator on the grant. “The microscale architecture of Microlyte® Matrix, which intimately conforms to a wound surface, will facilitate the synergistic action of the two metal ions to penetrate biofilms and kill multispecies bacteria hidden inside.”
“This novel antibiofilm dressing could significantly improve healing in high-risk surgeries and reduce the use of antibiotics and painful surgical debridement, saving billions of dollars in healthcare costs,” said Dr. Michael Schurr, MD, a critical care surgeon at Mission Hospital in Asheville, NC and a co-investigator on the grant.
Other investigators on the grant include Dr. Gaurav Pranami and Dr. Jeff Dalsin at Imbed, and Prof. Jonathan McAnulty of Surgical Sciences and Prof. Charles Czuprynski of Pathobiological Sciences in the School of Veterinary Medicine at University of Wisconsin-Madison.
Read more in the full press release here: Press Release